Sex-Specific Multiparameter Blood Test for the Early Diagnosis of Alzheimer's Disease

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Dec 23

PMID 36555310

Authors

Hyung Joon Cho

Philip Schulz

Lalitha Venkataraman

Richard J Caselli

Michael R Sierks

Affiliations

Soon will be listed here.

Abstract

Blood-based biomarkers are needed for the early diagnosis of Alzheimer's disease (AD). We analyzed longitudinal human plasma samples from AD and control cases to identify biomarkers for the early diagnosis of AD. Plasma samples were grouped based on clinical diagnosis at the time of collection: AD, mild cognitive impairment (MCI), and pre-symptomatic (preMCI). Samples were analyzed by ELISA using a panel of reagents against nine different AD-related amyloid-β (Aβ), tau, or TDP-43 variants. Receiver operating characteristic (ROC) curves of different biomarker panels for different diagnostic sample groups were determined. Analysis of all of the samples gave a sensitivity of 92% and specificity of 76% for the diagnosis of AD. Early-stage diagnosis of AD, utilizing only the preMCI and MCI samples, identified 88% of AD cases. Using sex-biased biomarker panels, early diagnosis of AD cases improved to 96%. Using the sex-biased panels, we also identified 6 of the 25 control group cases as being at high risk of AD, which is consistent with what is expected given the advanced age of the control cases. Specific AD-associated protein variants are effective blood-based biomarkers for the early diagnosis of AD. Notably, significant differences were observed in biomarker profiles for the early detection of male and female AD cases.

Citing Articles

Acute sleep deprivation in mice generates protein pathology consistent with neurodegenerative diseases.

Rowe R, Schulz P, He P, Mannino G, Opp M, Sierks M Front Neurosci. 2024; 18:1436966.

PMID: 39114483 PMC: 11303328. DOI: 10.3389/fnins.2024.1436966.

Traumatic Brain Injury in Mice Generates Early-Stage Alzheimer's Disease Related Protein Pathology that Correlates with Neurobehavioral Deficits.

Panayi N, Schulz P, He P, Hanna B, Lifshitz J, Rowe R Mol Neurobiol. 2024; 61(10):7567-7582.

PMID: 38411868 PMC: 11415463. DOI: 10.1007/s12035-024-04035-5.

Morphometric and Nanomechanical Screening of Peripheral Blood Cells with Atomic Force Microscopy for Label-Free Assessment of Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis.

Taneva S, Todinova S, Andreeva T Int J Mol Sci. 2023; 24(18).

PMID: 37762599 PMC: 10531602. DOI: 10.3390/ijms241814296.

Recombinant Antibody Fragments for Neurological Disorders: An Update.

Manoutcharian K, Gevorkian G Curr Neuropharmacol. 2023; 22(13):2157-2167.

PMID: 37646225 PMC: 11337690. DOI: 10.2174/1570159X21666230830142554.

Abnormal intraepidermal nerve fiber density in disease: A scoping review.

Thomas S, Enders J, Kaiser A, Rovenstine L, Heslop L, Hauser W Front Neurol. 2023; 14:1161077.

PMID: 37153658 PMC: 10157176. DOI: 10.3389/fneur.2023.1161077.

References

Nelson P, Brayne C, Flanagan M, Abner E, Agrawal S, Attems J . Frequency of LATE neuropathologic change across the spectrum of Alzheimer's disease neuropathology: combined data from 13 community-based or population-based autopsy cohorts. Acta Neuropathol. 2022; 144(1):27-44. PMC: 9552938. DOI: 10.1007/s00401-022-02444-1. View

Folstein M, Folstein S, McHugh P . "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3):189-98. DOI: 10.1016/0022-3956(75)90026-6. View

Yang T, Hong S, OMalley T, Sperling R, Walsh D, Selkoe D . New ELISAs with high specificity for soluble oligomers of amyloid β-protein detect natural Aβ oligomers in human brain but not CSF. Alzheimers Dement. 2013; 9(2):99-112. PMC: 3604133. DOI: 10.1016/j.jalz.2012.11.005. View

Williams S, Venkataraman L, Tian H, Khan G, Harris B, Sierks M . Novel atomic force microscopy based biopanning for isolation of morphology specific reagents against TDP-43 variants in amyotrophic lateral sclerosis. J Vis Exp. 2015; (96). PMC: 4354642. DOI: 10.3791/52584. View

Baloh R . TDP-43: the relationship between protein aggregation and neurodegeneration in amyotrophic lateral sclerosis and frontotemporal lobar degeneration. FEBS J. 2011; 278(19):3539-49. PMC: 3177991. DOI: 10.1111/j.1742-4658.2011.08256.x. View

Meyer P, Binette A, Gonneaud J, Breitner J, Villeneuve S . Characterization of Alzheimer Disease Biomarker Discrepancies Using Cerebrospinal Fluid Phosphorylated Tau and AV1451 Positron Emission Tomography. JAMA Neurol. 2020; 77(4):508-516. PMC: 6990861. DOI: 10.1001/jamaneurol.2019.4749. View

Williams S, Schulz P, Rosenberry T, Caselli R, Sierks M . Blood-Based Oligomeric and Other Protein Variant Biomarkers to Facilitate Pre-Symptomatic Diagnosis and Staging of Alzheimer's Disease. J Alzheimers Dis. 2017; 58(1):23-35. DOI: 10.3233/JAD-161116. View

Barkhordarian H, Emadi S, Schulz P, Sierks M . Isolating recombinant antibodies against specific protein morphologies using atomic force microscopy and phage display technologies. Protein Eng Des Sel. 2006; 19(11):497-502. DOI: 10.1093/protein/gzl036. View

Henchcliffe C, Dodel R, Beal M . Biomarkers of Parkinson's disease and Dementia with Lewy bodies. Prog Neurobiol. 2011; 95(4):601-13. DOI: 10.1016/j.pneurobio.2011.09.002. View

10.

Zameer A, Schulz P, Wang M, Sierks M . Single chain Fv antibodies against the 25-35 Abeta fragment inhibit aggregation and toxicity of Abeta42. Biochemistry. 2006; 45(38):11532-9. DOI: 10.1021/bi060601o. View

11.

Emadi S, Liu R, Yuan B, Schulz P, McAllister C, Lyubchenko Y . Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments. Biochemistry. 2004; 43(10):2871-8. DOI: 10.1021/bi036281f. View

12.

Ferreira S, Klein W . The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. Neurobiol Learn Mem. 2011; 96(4):529-43. PMC: 4390395. DOI: 10.1016/j.nlm.2011.08.003. View

13.

Albert M, DeKosky S, Dickson D, Dubois B, Feldman H, Fox N . The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7(3):270-9. PMC: 3312027. DOI: 10.1016/j.jalz.2011.03.008. View

14.

LaFerla F, Green K, Oddo S . Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci. 2007; 8(7):499-509. DOI: 10.1038/nrn2168. View

15.

Williams S, Schulz P, Sierks M . Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases. Eur J Neurosci. 2015; 43(1):3-16. PMC: 4718789. DOI: 10.1111/ejn.13056. View

16.

Blennow K, Hampel H, Weiner M, Zetterberg H . Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010; 6(3):131-44. DOI: 10.1038/nrneurol.2010.4. View

17.

Williams S, Peltz C, Yaffe K, Schulz P, Sierks M . CNS disease-related protein variants as blood-based biomarkers in traumatic brain injury. Neurology. 2018; 91(15):702-709. PMC: 6177276. DOI: 10.1212/WNL.0000000000006322. View

18.

Renner M, Lacor P, Velasco P, Xu J, Contractor A, Klein W . Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Neuron. 2010; 66(5):739-54. PMC: 3111138. DOI: 10.1016/j.neuron.2010.04.029. View

19.

Clavaguera F, Bolmont T, Crowther R, Abramowski D, Frank S, Probst A . Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol. 2009; 11(7):909-13. PMC: 2726961. DOI: 10.1038/ncb1901. View

20.

Liu R, Yuan B, Emadi S, Zameer A, Schulz P, McAllister C . Single chain variable fragments against beta-amyloid (Abeta) can inhibit Abeta aggregation and prevent abeta-induced neurotoxicity. Biochemistry. 2004; 43(22):6959-67. DOI: 10.1021/bi049933o. View